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system for NSCLC considers the size and location of
the primary tumor (T), the involvement of regional
lymph nodes (N), and the presence of distant metastases
(M).2 The standard treatment of patients with stage I
NSCLC (T1-2 N0) is resection of the primary tumor (no
adjuvant therapy). However, even after complete resec-
tion, 5-year survival is only 55% to 72% in this group
of patients, predominately because of the development
of distant metastases.2-7
An operation alone is considered the standard therapy
for patients with stage I NSCLC. To select a subgroup
of patients with stage I disease who might benefit from
adjuvant therapy, investigators have attempted to identi-
fy factors that predict poor prognosis, including analy-
sis of performance status, the subtype and size of the
primary tumor, the degree of tumor differentiation, the
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and women in the United States.1 The current staging
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mitotic rate, and the evidence of lymphatic or vascular
invasion.5,7-13 These factors indirectly measure tumor
aggressiveness and have not identified a group of stage
I patients who benefit from adjuvant therapy.
Recent interest has focused on the identification of
biologic markers that predict early recurrence and
death in patients with lung cancer. Advances in molec-
ular biology, specifically the study of oncogenes and
other molecular markers, have been applied in the
development of a prognostic index of recurrence in
patients with stage I NSCLC.13-26 These serum and tis-
sue markers may be classified by the mechanism of
action that results in metastases: growth regulation, cell
cycle regulation, apoptosis, angiogenesis, and cellular
adhesion. Local tumor expansion requires growth-reg-
ulating proteins (epidermal growth factor receptor
[EGFr], the protooncogene erb-b2); apoptosis proteins
(p53, bcl-2); and cell cycle–regulating proteins (retino-
blastoma recessive oncogene [rb], KI-67). Local tumor
invasion requires angiogenesis (factor viii). The devel-
opment of distant metastases involves the expression of
adhesion proteins (CD-44, sialyl Tn, blood group A).
Stratification of patients without lymph node involve-
ment, according to a prognostic risk model, might
select a group of high-risk patients who would benefit
from adjuvant therapy. This study evaluates a panel of
molecular biologic markers in patients with stage I
NSCLC after complete resection to determine the prog-
nostic value of each marker and to create a biologic risk
model. The molecular markers assessed in this study
encompass various biologic mechanisms of metastases.
Methods
From January 1, 1980, until December 31, 1992, 6510 con-
secutive patients with documented NSCLC were evaluated at
the Comprehensive Cancer Center at Duke University Medical
Center. Inclusion criteria for entry into the study population
included pathologic stage I NSCLC (T1 N0 M0 or T2 N0 M0)
by the International System of Staging for Lung Cancer,2 com-
plete resection, no adjuvant therapy, minimum 60-day sur-
vival, and availability of pathologic material. During this peri-
od, 408 patients met these criteria; all patients in this study
have been followed for at least 60 months (5 years).
Each case was reviewed by a pathologist to ascertain tumor
size and cell type and to exclude the involvement of hilar and
mediastinal lymph nodes. Only squamous cell, large cell, and
adenocarcinoma variants are included in this analysis. The
greatest dimension of the tumor was measured in centimeters;
the primary lesion was carefully examined for the presence of
visceral pleural involvement, lymphatic vessel invasion, and
vascular invasion.
Immunohistochemical analyses were performed on 2 paraf-
fin blocks of resected lung tissue for each patient in the study,
obtained after approval of the Human Subjects Review Com-
mittee protocol. The immunohistochemical analyses have
been previously described.13-15 In brief, after paraffin micro-
tome sectioning (4 to 6 mm), slide labeling, and deparaffin-
ization with xylene and ethanol, antigen retrieval was com-
pleted after microwaving and phosphate-buffered saline
solution washing. The sections were incubated with primary
monoclonal antibody to EGFr, erb-b2, p53, bcl-2, rb, KI-67,
factor viii, CD-44 blood group antigen A (BioGenex Labora-
tories, San Ramon, Calif), and Sialyl-Tn (Dako, Carpinteria,
Calif). Incubation with the secondary antibody (horseradish
peroxidase) was subsequently performed, followed by devel-
opment with diaminobenzidine and counterstain with methyl
green or hematoxylin.
Immunohistochemical data were recorded without the
knowledge of patient outcome. Analysis of p53, rb, bcl-2,
EGFr, erb-b2, sialyl-Tn, CD-44, and blood group antigen A
were analyzed by 2 independent observers. Known positive
tumors and normal lung tissue were used as positive and neg-
ative controls, respectively. Blocks were graded positive
when widespread staining was present, with an intensity of at
least 2 (50% or more positive) on a scale of 0 to 3. Both
observers had to rate a 2 or better for each block to be con-
sidered positive. The presence of nuclear staining of p53 was
an indication of mutation for the p53 gene.15 The KI-67 pro-
liferation index was determined by computerized static image
cytometry of 10 consecutive high-powered fields, compared
with a background established with control antibody.
Analysis of angiogenesis factor viii included the center, the
periphery, and the hottest area, with the use of computerized
static image cytometry of 10 consecutive high-powered
fields.
Statistical analysis. All marker analyses were blinded to
patient outcome. The log-rank test and Cox proportional haz-
ards model were used to examine the relationship between
cancer-specific survival and various potential prognostic fac-
tors individually, comprising immunostaining for rb, EGFr,
erb-b2, bcl2, p53, CD-44, blood-group A antigen, sialyl-Tn,
and the KI-67 proliferation index and factor viii microvessel
count. The joint effect of the variables with P < .2 for a uni-
variate association with cancer-death was also examined with
the Cox model; the .10 level of significance was used for
entering or removing a covariable for this model. Cancer-spe-
cific survival was defined as the time between the operation
and the last follow-up or cancer death. If a patient died with-
out cancer recurrence, the patient’s survival time was cen-
sored at the time of death.13-15
Results
The mean age of the patients was 62.9 ± 8.9 years.
There were 269 men (66%) and 139 women (34%;
Table I). In this study of 408 patients with pathologi-
cally confirmed stage I NSCLC treated by resection
alone, there were 149 deaths from cancer; the actual 5-
year survival was 64%.
There was no significant difference in survival by
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histologic evidence or by the method of resection.
Expression of the molecular biologic markers ranged
from 23% to 60% (Table I). Univariate analysis of the
relationship between survival and the panel of molecu-
lar biologic markers was statistically significant for
p53, erb-b2, rb, KI-67, factor viii, and CD-44 (Table
II). Multivariable analysis (Table III) demonstrated sig-
nificantly elevated risk for the following molecular
markers: p53 (Fig 1), factor viii (Fig 2), erb-b2 (Fig 3),
CD-44 (Fig 4); and rb (Fig 5).
With multivariable analysis of the entire panel of
molecular markers, a prognostic risk model for survival
demonstrates significantly decreased survival accord-
ing to the total number of factors involved (Fig 6).
Furthermore, analysis of only the factors demonstrated
to be independent multivariable risk factors similarly
demonstrates that survival is related to the number of
factors involved (Fig 7). There was no significant dif-
ference in the prognostic information provided by the
molecular marker analysis among patients with T1
tumors, as compared with the entire population (Fig 8).
Discussion
The goals of this study were to evaluate a panel of
molecular biologic markers in a large, single-institution
population of patients with stage I NSCLC after resec-
tion and to develop a prognostic model based on the
involvement of these molecular variables, independent
of other variables. The development of a risk model for
patients with stage I disease, in whom the failure rate
for an operation alone is 28% to 45%,2-7 might eventu-
ally be used to select a subgroup of patients who would
benefit from adjuvant therapy.
Conventional histopathologic variables have been
investigated to determine the prognosis and to assign
the therapy, such as the size and subtype of the prima-
ry tumor and the degree of differentiation, mitotic rate,
and evidence of vascular invasion. Among patients
with stage I NSCLC (T1 N0 or T2 N0), there is a clear
5-year survival advantage for patients with T1 (67%) as
compared with T2 (57%) disease.2 This relationship is
consistent for both size (≤ 3 cm) and location (no pleur-
al involvement).17 This difference in survival stimulat-
ed the latest modification of the international staging
system, which categorizes T1 N0 M0 as stage IA and
T2 N0 M0 as stage IB. Nevertheless, this magnitude of
this survival difference is overshadowed by the survival
differences between stages I, II, and III. The adminis-
tration of adjuvant therapy has not yet been shown to
benefit patients with stage I disease, although this issue
is the focus of ongoing multi-institutional cooperative
group trials.
The relationship of the degree of differentiation of
the primary tumor and survival has been analyzed in
patients with stage I NSCLC.13 Poorly differentiated or
undifferentiated tumors are defined as negative prog-
nostic factors by univariate analysis, but not multivari-
able analysis. Mitotic rate and pulmonary vascular
invasion have been demonstrated to be negative prog-
nostic risk factors; however, this variable, like other
Table I. Expression of molecular biologic markers
Oncogenic group Marker No. positive (%)
Growth factor EGFr 212 (52)
erb-b2 104 (25)
Cell cycle factor rb (normal) 228 (56)
KI-67 (elevated) 205 (50)
Apoptosis factor p53 176 (43)
bcl-2 95 (23)
Angiogenesis factor Factor viii 246 (60)
Metastatic adhesion factor CD-44 132 (32)
Sialyl Tn 170 (42)
Blood group 63/101 (62)*
antigen A
*Thirty-eight percent of the 101 patients with blood type A.
Table II. Univariate survival analysis for molecular
biologic markers
5-Year survival (%)
Oncogenic group Marker Positive Negative P value
Growth factor EGFr 63 61 .6
erb-b2 47 67 .002*
Cell cycle factor rb 64 60 .2*
KI-67 58 66 .06*
Apoptosis factor p53 52 70 .001*
bcl-2 64 61 .5
Angiogenesis factor Factor viii 56 70 .008*
Metastatic adhesion CD-44 54 66 .02*
factor Sialyl Tn 60 63 .6
Blood group 75 67 .4
antigen A
*Significant at P ≤ .2.
Table III. Multivariable survival analysis for molecu-
lar biologic markers
Group Marker Hazard ratio P value
Growth factor erb-b2 1.429 .044
Cell cycle factor rb 0.747 .0838
Apoptosis factor p53 1.63 .037
Angiogenesis factor Factor viii 1.47 .033
Metastatic adhesion factor CD-44 1.399 .05
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histopathologic variables, is found to be present in a
minority of patients with stage I disease.9,13 The use of
histopathologic variables (tumor size and subtype,
mitotic rate, degree of differentiation, and vascular
invasion) to construct a risk model is limited by the low
prevalence and the discontinuous nature of the vari-
ables.
Molecular biologic markers have recently been stud-
ied in lung cancer to determine prognostic importance.
Matsuyama and colleagues16 demonstrated the prog-
nostic significance of angiogenesis using the immuno-
histochemical identification of CD34, in which angio-
genesis was an independent predictor of death and the
presence of hematogenous metastases. This study was
not specific to stage I disease, and only 1 molecular
marker was studied. Duarte and associates18 compared
factor viii to CD31 in determining the degree of angio-
genesis in patients with stage I disease. This study
demonstrated that factor viii was superior to CD31 as
an indicator of tumor angiogenesis and malignant
potential (hazard ratio, 2.9). This study and numerous
other studies have examined the relationship of a single
oncogene or molecular marker on the survival in
patients with lung cancer, without addressing the spec-
trum of oncogenic mechanisms in the molecular biology
of lung cancer.14,19-21
In a previous study by 1 of the authors (D.H.H.), a
panel of 4 molecular markers were applied to patients
with stage I NSCLC: angiogenesis factor viii, p53, erb-
b2, and KI-67.13 Each factor had independent prognos-
tic significance. Moreover, multivariable analysis
demonstrated a powerful relationship among the num-
ber of molecular markers involved, in terms of survival.
In patients with 0 markers, 1 marker, 2 markers, or 3 to
4 markers, the 5-year survival was 81%, 71%, 54%,
and 45%, respectively. Finally, in a group of 244
Fig 1. Kaplan-Meier analysis of cancer-specific survival for
p53.
Fig 2. Kaplan-Meier analysis of cancer-specific survival for
factor viii.
Fig 3. Kaplan-Meier analysis of cancer-specific survival for
erb-b2.
Fig 4. Kaplan-Meier analysis of cancer-specific survival for
CD-44.
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patients, a pathologic substaging system was devel-
oped, with 6 molecular markers.25 This staging system
effectively stratifies patients in terms of risk of recur-
rence according to the number of markers involved.
This study identified only 3 molecular markers that
were statistically associated with recurrence: p53, K-
ras mutation, and the lack of H-ras p21 expression.
In the current study, we evaluate a panel of 10 mole-
cular biologic markers in 408 patients with stage I
NSCLC after complete resection, the largest population
ever studied with molecular markers. To create a model
of molecular biologic substaging, we have chosen
markers that represent 5 separate oncogenic pathways:
growth regulation, cell cycle regulation, apoptosis,
angiogenesis, and metastatic adhesion.
EGFr, which is encoded by the protooncogene erb-
b1, is an important contributing factor in supporting
uncontrolled tumor growth. The protooncogene erb-b2,
which shows extensive homology to erb-b1, encodes a
membrane-associated tyrosine kinase that also serves
as a growth factor receptor.
Cell cycle–regulating proteins have a direct effect on
tumor clonal expansion. The rb interacts with p53 in
regulating gene expression in the nucleus. The tumor
proliferation marker KI-67 is a nonhistone nuclear pro-
tein that is expressed in cells that are near mitosis. The
KI-67 proliferation index has been demonstrated to be
associated with decreased survival in several stud-
Fig 5. Kaplan-Meier analysis of cancer-specific survival for
rb.
Fig 6. Analysis of cancer-specific survival according to the
involvement of all molecular markers.
Fig 7. Analysis of cancer-specific survival according to the
involvement of the 5 molecular markers that were significant
in the multivariable analysis.
Fig 8. Analysis of cancer-specific survival among patients
with T1 tumors according to the involvement of the 5 molec-
ular markers that were significant in the multivariable analy-
sis. Numbers on the Kaplan-Meier survival curves represent
censors data. Data for the Kaplan-Meier survival estimates
were truncated at 72 months survival for graph creation.
There are 160 patients with more than 72 months survival
(range, 72-201 months) who do not appear as tic marks on the
curves.
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ies.13,15 Although the KI-67 proliferation index is relat-
ed to the mitotic rate, KI-67 is a more prevalent prolif-
eration marker and thus may be assessed in a greater
number of patients.
Mutations in recessive oncogenes that code for apop-
tosis have been demonstrated to allow unregulated cell
growth and contribute to the proliferation of malignant
tumors. Normal p53 encodes a nuclear phosphoprotein
required to regulate cell growth; mutated p53 stimu-
lates unregulated cell growth and promotes malignan-
cy. Similarly, bcl-2 is expressed in normal epithelial
cells and encodes a protein that regulates cell viability
and inhibits apoptosis. Although the overexpression of
bcl-2 is associated with uncontrolled cell growth, it has
been associated with improved survival when found in
lung malignancies.26
Tumor cells initially obtain nutrition from central dif-
fusion from surrounding pulmonary parenchyma. Once
a colony outgrows its blood supply, central necrosis
occurs. This ischemic process signals angiogenesis in
the tumor, allowing capillary ingrowth into the tumor
and further growth. The presence of angiogenesis fac-
tor viii has already been demonstrated as a powerful
negative prognostic factor. Immunohistochemical anal-
ysis of factor viii allows for quantification of microves-
sel presence in a tumor. Studies have shown that the
hottest area microvessel number is correlated with
recurrence and death in patients with NSCLC.9,13 Al-
though the microvessel count using factor viii and the
histologic determination of pulmonary vascular inva-
sion both have negative prognostic value, the preva-
lence of factor viii is significantly higher and allows
application to a greater number of patients in a prog-
nostic model.
The presence of blood vessels in the tumor allows
cells to be shed into the circulation. The development
of distant metastases requires the expression of cellular
adhesion proteins, which are involved in local tumor
invasion and metastases. CD-44 is an integral mem-
brane glycoprotein that functions as a receptor for the
extracellular matrix glycan, halyuronan. The loss of
expression of blood group A antigen in patients with
blood group A allows the expression of immature blood
group antigens, which promotes metastatic adhesion
and is postulated to confer metastatic potential.22
Aberrant glycosylation of mucins results in the expres-
sion of sialyl-Tn antigens in various malignant neo-
plasms,23 and the expression of sialyl-Tn is associated
with tumor progression, local invasion, and adhesion of
tumor cells on the endothelium of distant vessels.24
In this molecular biologic risk model, 5 oncogenic
mechanisms are represented by the panel of 10 markers
(Table I). Multivariable analysis confirmed prognostic
value for 5 of the markers, including 1 marker from
each oncogenic group (Table III).
The factor with the strongest independent prognostic
value was p53 (hazard ratio, 1.63; P = .037), support-
ing previous studies. Kaplan-Meier survival analysis
demonstrates the negative prognostic value of the p53
overexpression, which is associated with 5-year sur-
vival of 52%, compared with 70% in patients with nor-
mal p53 (Fig 1).
As in previous studies, hot area angiogenesis factor
viii was associated with significantly decreased sur-
vival (hazard ratio, 1.47; P = .003). The 5-year survival
in patients with hot area angiogenesis was 56%, com-
pared with 70% in those patients with low factor viii
counts (Fig 2).
The presence of the protooncogene erb-b2 was also a
strong negative prognostic factor (hazard ratio, 1.429;
P = .044). The 5-year survival of patients with erb-b2
was 47%, compared with 67% in patients without this
marker (Fig 3).
The metastatic adhesion protein CD-44 was also neg-
ative prognostic factor (hazard ratio, 1.399; P = .05).
The 5-year survival of patients with CD-44 was 54%,
compared with 67% in patients without CD-44 (Fig 4).
The presence of rb, a cell cycle regulator, was
demonstrated to be a positive prognostic factor in this
study; the absence of rb was associated with signifi-
cantly decreased survival; the 5-year survival of
patients with rb was 63%, compared with 55% in
patients without rb (Fig 5).
In this study, the prevalence of the molecular markers
ranged from 32% to 68%, allowing most patients to be
analyzed for 1 or more prognostic factors. When this
group of patients was analyzed for the impact of the
number of markers on survival, another important rela-
tionship appeared. Survival was strongly associated
with the number of molecular risk factors, and 3 groups
were created to stratify the risk of death. Patients with
0-3, 4-5, and 6-9 markers have 5-year survival of 76%,
62%, and 48%, respectively (Fig 6). The Kaplan-Meier
survival analysis was also performed for the panel of 5
markers that were found to be significant in the multi-
variable risk analysis. The 5-year survival for patients
with 0-1 markers, 2 markers, and 3-5 markers was
77%, 62%, and 58%, respectively (Fig 7).
A panel of 10 molecular biologic markers were ana-
lyzed immunohistochemically in a large, single-institu-
tion population of patients with stage I NSCLC after
complete resection. Immunohistochemical analysis is
rapid, reproducible, relatively inexpensive, and gener-
ally available in most hospitals. This panel of markers
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represents 5 oncogenic mechanisms, and multivariable
analysis identified 1 marker in each oncogenic group as
a significant prognostic factor (p53, factor viii, erb-b2,
CD-44, and rb). Although each factor alone carries
independently significant prognostic information, risk
stratification is further enhanced by analyzing patient
survival according to the number of risk factors
involved. In this model, patients with 3-5 molecular
markers are at a significantly increased risk of cancer-
related death, despite complete surgical resection for
stage I NSCLC. Although adjuvant therapy has not been
demonstrated to be effective in patients with stage I dis-
ease after resection, it is postulated that risk stratifica-
tion will identify a group of patients with a sufficiently
elevated risk of death to justify adjuvant therapy.
This prognostic model uses molecular markers of 5
oncogenic mechanisms to analyze the risk of cancer-
related death. The advantages of this model include the
ability to assess direct oncogenic mechanisms rather
than the indirect indices of histopathologic variables
and to analyze these variables in most patients in the
population. Furthermore, the variables are related
mechanistically, and the use of a group of factors to
improve risk stratification is a logical approach. The
prospective validation of this model is recommended
before its application to assign adjuvant chemotherapy
after complete resection in patients with completely
resected NSCLC.
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Discussion
Dr John R. Benfield (Sacramento, Calif). I am delighted
that the Program Committee chose to accept your paper
because it is a preview to thoracic operations in the future. It
is crucial that we not be intimidated by what you have pre-
sented today.
In a sense, your work is a follow-up to our 1988 presenta-
tion to The American Association for Thoracic Surgery
(Benfield JR, Wain JC, Derrick M, et al. Biochemical and
cytogenetic studies of human lung cancers. J Thorac
Cardiovasc Surg 1988;96:840-8) and to Dr John Minna’s pre-
sentation to this Association in 1990, which was titled “The
Cellular and Molecular Biology of Lung Cancer.” The fact
that your multidisciplinary group is led by you and other sur-
geons will insure that thoracic surgeons continue to lead in
the fight against lung cancer.
The hypothesis of your paper could be restated as follows:
Each lung cancer has inherent biologic characteristics that
allow one to predict its behavior and to plan therapy at the out-
set. In practicality, you are addressing the clinical frustration
when we now operate on patients and believe them cured, only
to find that at least 20% of such patients later experience
recurrent cancer. What you are trying to find out is how to
select patients for whom operation alone suffices as compared
with those who require adjuvant or induction therapy even
though their cancers appear to be early stage by current crite-
ria. Is this a reasonable way to restate your hypothesis? 
Dr D’Amico. Very elegant, yes.
Dr Benfield. I think we are looking forward, perhaps in
another 5 years, to the opportunity to work up each patient’s
cancer in addition to studying the patient as we now do. Years
hence, when a patient with lung cancer is referred to us, we
will do a needle biopsy and from that specimen and from
serologic specimens we will look at a molecular biologic
panel of information. Such studies will tell us how aggressive
each cancer is likely to be and what form of induction or adju-
vant therapy should be given.
Your study is descriptive and not a study of mechanisms.
Therefore, quite correctly, you have called for a prospective
validation of the significance of the markers you have exam-
ined. There is a need to do this validation before you use your
current results as the basis for a phase II adjuvant therapy
study. In the meantime there is an opportunity to apply the
techniques with which you have gained experience in sam-
ples obtained from patients enrolled in ongoing phase III lung
cancer therapy studies.
To do the studies of mechanisms that I suggest, it will be
difficult to get enough samples from patients alone. Thus I
believe it would be helpful to carry forward in your work with
animal models of lung cancer. Such models can be studied in
serial fashion during carcinogenesis, and this should give
more information than one could get from studies limited to
patients with lung cancer. 
How close are you to being able to apply your immunohis-
tochemical techniques to fine-needle aspirate or cytologic
specimens? What are your thoughts about the use of animal
models of lung cancer as a supplement to the work that is
ongoing at Duke?
Dr D’Amico. In terms of using the data that we have in ret-
rospectively analyzing patients who have already been treat-
ed, our laboratory has concentrated on patients with stage I
disease, so we’re taking patients who have never been treated
with adjuvant therapy. But, the preliminary work that our lab-
oratory has done was used to construct the correlative science
portion of cancer and leukemia group B study 9633, in which
patients with T2 N0 are randomized to receive observation or
adjuvant chemotherapy. All the patients, whether they are
observed or treated, are going to be analyzed for the panel of
molecular markers. So we will have these data, although the
markers are not being used to assign chemotherapy; we will
have in a prospective study the analysis of markers in patients
who were observed or were given chemotherapy.
That addresses 1 of your points. To specifically address
your questions, you outlined the model that we would have
outlined in terms of how we would use this data to treat
patients in the future, that is to know prospectively the mole-
cular characteristics of the tumor from a needle biopsy and to
use that to assign therapy before an operation. If for patients
with stage I disease with high-risk markers it were to be
shown that induction therapy were superior to adjuvant ther-
apy as it has been shown for patients with stage IIIA disease,
that would definitely be the way to go. There are some mark-
ers that we can analyze with small cytologic specimens; it is
easy to analyze a small number of cells for P53 or for erb-b2,
whereas analysis of other factors (such as angiogenesis)
require that the tumor be intact to perform microvessel
counts. So, some markers could be analyzed at the cytologic
level; we would have to advance our techniques or use other
ways such as another polymerase chain reaction to evaluate
these markers. And that we can do.
To answer your second question in terms of actually getting
at the mechanism of the molecular biology of lung cancer, I
agree with you that that would require an animal model. The
model that we have described is not really a mechanistic
model; it is a descriptive model. We understand the difficulty
in establishing animal models of lung cancer and that some of
the difficulties that your work has shown can be overcome.
And we understand the importance of animal models to get at
the mechanistic level; we have not undertaken that, and I do
not know if we will in the future.
